India CDSCO archive
This page is an archival note. This site previously indexed India's Central Drugs Standard
Control Organisation (CDSCO) drug-quality alerts. That dataset has been archived
and the site now focuses on United States FDA data. This page is marked noindex and is
not part of the main sitemap.
The previous dataset
In its earlier form, this project was an independent index of public CDSCO publications — drug approvals, Not-of-Standard-Quality (NSQ) alerts and spurious-drug alerts — reorganised so they were easier to search, date and cross-reference. The processed CDSCO data remains in the project repository as a historical archive and is not deleted.
The last-known archived state of the CDSCO dataset recorded approximately 424 alert entries (of which 235 NSQ and 15 spurious), with a latest record date of 2025-08-28.
Why it was archived
The CDSCO source listing that this site depended on stopped updating reliably: the public notifications listing page ceased to surface new machine-readable drug-quality entries on a dependable schedule, which meant the dataset could no longer be kept fresh through the same automated path. Rather than present a dataset that might silently go stale, the project pivoted to United States FDA data, where openFDA provides dependable, documented, machine-readable APIs for drug recalls and shortages. This is an operational decision about data dependability, not a judgement about CDSCO or the information it publishes.
Limits of the archived source
The CDSCO dataset always carried explicit limitations: much CDSCO content is published as scanned PDFs that are not machine-readable without OCR (which was out of scope), so coverage was partial by construction and most alert particulars remained inside the linked documents. Those same limits apply to the archived data. For any authoritative information about Indian drug regulation, CDSCO remains the only authoritative source.
The current FDA dataset
The site now indexes U.S. FDA data. Start at the homepage, or go directly to FDA drug recalls, FDA drug shortages, FDA drug approvals, or manufacturer regulatory signals. The FDA data sources page documents the new sources in full.